Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 10/20 | 0.63 |
| ▸ | CTSK | P43235 | 9/20 | 0.63 |
| ▸ | CTSB | P07858 | 4/20 | 0.63 |
| ▸ | CTSL | P07711 | 2/20 | 0.63 |
| ▸ | ATM | Q13315 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | AKT1 | P31749 | 1/20 | 0.56 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.51 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.51 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.51 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.51 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14775736 | 1.00 | CTSS (0.63) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL5551983 | 0.85 | CTSS (0.54) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL5556499 | 0.82 | CTSS (0.56) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL9383811 | 0.82 | CTSS (0.58) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL9383807 | 0.82 | CTSS (0.58) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL4850512 | 0.81 | ATM (0.55) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL7622856 | 0.81 | ATM (0.55) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL21010315 | 0.81 | CTSS (0.79) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL10040933 | 0.81 | CTSS (0.79) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL2440946 | 0.81 | CTSS (0.79) | CTSSCTSKCTSBCTSLAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431684-B2 | Process for the preparation of ibodutant (MEN15596) and related intermediates | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2013-04-30 | — | — | US | disclosed |
| US-20120065370-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2012-03-15 | — | — | US | disclosed |
| WO-2010133306-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065370-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | DDT, BBOX1, IMPDH2 | CTSS 4614/4885CTSK 4497/4885CTSB 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.